Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Non-Current Assets (2022 - 2025)

Historic Non-Current Assets for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $140.6 million.

  • Centessa Pharmaceuticals' Non-Current Assets rose 24007.64% to $140.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $552.9 million, marking a year-over-year increase of 21859.83%. This contributed to the annual value of $40.4 million for FY2024, which is 1055.28% down from last year.
  • According to the latest figures from Q3 2025, Centessa Pharmaceuticals' Non-Current Assets is $140.6 million, which was up 24007.64% from $191.8 million recorded in Q2 2025.
  • Over the past 5 years, Centessa Pharmaceuticals' Non-Current Assets peaked at $191.8 million during Q2 2025, and registered a low of $993000.0 during Q1 2022.
  • In the last 4 years, Centessa Pharmaceuticals' Non-Current Assets had a median value of $42.5 million in 2023 and averaged $56.3 million.
  • Per our database at Business Quant, Centessa Pharmaceuticals' Non-Current Assets soared by 263715.39% in 2023 and then plummeted by 1055.28% in 2024.
  • Quarter analysis of 4 years shows Centessa Pharmaceuticals' Non-Current Assets stood at $6.6 million in 2022, then soared by 588.32% to $45.2 million in 2023, then fell by 10.55% to $40.4 million in 2024, then soared by 248.18% to $140.6 million in 2025.
  • Its last three reported values are $140.6 million in Q3 2025, $191.8 million for Q2 2025, and $180.1 million during Q1 2025.